Filing Analysis
Forte Biosciences, Inc. has completed its acquisition by argenx BV, resulting in the company becoming a wholly owned subsidiary. The transaction involved a cash tender offer at $77.00 per share and the subsequent delisting of the company's common stock from the NASDAQ.
🚩 Red Flags
- Complete cessation of independent corporate existence (becomes a wholly owned subsidiary).
- Total removal of existing board of directors and officers.
- Termination of SEC reporting obligations (Form 15 filing).
📋 Key Facts
- Transaction completed on August 27, 2026.
- Acquisition price: $77.00 per share in cash.
- Total transaction value (including options, RSUs, and warrants) was approximately $2.2 billion.
- The offer was successful, with 19,894,879 shares (87.13% of outstanding shares) validly tendered.
- The company is being delisted from NASDAQ and will file Form 15 to terminate its reporting obligations.
- All previous directors and officers have ceased their roles as of the effective time.
Forte Biosciences, Inc. has entered into a definitive merger agreement to be acquired by argenx BV in an all-cash transaction. The deal is structured as a two-step tender offer followed by a merger, with the Board unanimously recommending that shareholders accept the $77.00 per share offer.
🚩 Red Flags
- Significant termination fee of $65 million which could impact company liquidity if a deal is terminated for a superior proposal.
- Transaction subject to HSR Antitrust waiting period and other customary closing conditions.
📋 Key Facts
- Acquisition price: $77.00 per share in cash, net to the seller.
- Acquirer: argenx BV (a private Belgian company) and its subsidiary Avena Merger Sub Inc.
- Transaction structure: Two-step transaction consisting of a tender offer followed by a merger.
- Minimum condition: Tender offer must result in >50% of outstanding shares being tendered/owned by Parent/affiliates.
- Termination fee: $65 million payable by the Company under specific circumstances (e.g., entering a Superior Offer agreement).
- Board recommendation: Unanimous recommendation to accept the offer.
- Closing timeline: Tender offer expected to commence within 10 business days of July 26, 2026.
Forte Biosciences announced positive results from its FB102 double-blind placebo-controlled Phase 1b study in vitiligo. The company hosted a conference call to review the clinical data presentation.
📋 Key Facts
- Announced positive results from the FB102 Phase 1b study for the treatment of vitiligo.
- The study was a double-blind, placebo-controlled trial.
- Company held a conference call on July 9, 2026, to discuss clinical data.
- Data presentation provided as Exhibit 99.2.
Forte Biosciences, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025. The filing consists of a press release containing the company's recent operational and financial performance metrics.
📋 Key Facts
- Reporting date: November 14, 2025
- Period covered: Quarter ended September 30, 2025
- The filing includes Exhibit 99.1 (Press Release) regarding financial results.
Forte Biosciences, Inc. filed an 8-K to report its financial results for the quarter ended June 30, 2025 and provided an updated corporate presentation.
📋 Key Facts
- Reported quarterly financial results for the period ending June 30, 2025 (Item 2.02).
- Released an updated corporate presentation intended for use with investors and analysts (Item 8.01).
- Filed on August 14, 2025.
Forte Biosciences, Inc. entered into an underwriting agreement to conduct a public offering of 5,630,450 shares of common stock and 619,606 pre-funded warrants at $12.00 per share. The company expects gross proceeds of approximately $75 million to fund operations into 2027.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 5.6 million new shares.
- Issuance of pre-funded warrants which can lead to future equity dilution.
📋 Key Facts
- Offering size: 5,630,450 shares of common stock and 619,606 pre-funded warrants.
- Pricing: $12.00 per share; Pre-Funded Warrants priced at $11.999 per warrant.
- Gross proceeds expected: ~$75.0 million (assuming no over-allotment exercise).
- Net proceeds estimated: ~$70.0 million to $80.5 million depending on option exercise.
- Use of funds: Expected to fund operating expenses and capital expenditures into 2027.
- Underwriters include TD Securities (USA) LLC, Evercore Group L.L.C., Guggenheim Securities, LLC, and Chardan Capital Markets, LLC.
- Expected closing date: On or about June 26, 2025.
Forte Biosciences, Inc. announced positive Phase 1b clinical trial data for its lead program, FB102, targeting celiac disease. The company held a conference call to review the study results and updated its corporate presentation.
📋 Key Facts
- Announced positive data from a Phase 1b trial in celiac disease for lead program FB102 on June 23, 2025.
- Hosted a conference call to review clinical study results.
- Released an updated corporate deck and detailed Phase 1b results presentation.
Forte Biosciences, Inc. held its 2025 annual meeting of stockholders on May 29, 2025. The filing reports the election of Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm.
🚩 Red Flags
- High number of 'Votes Withheld' for Director nominee David Gryska (approx. 24% of represented shares).
📋 Key Facts
- Annual Meeting held on May 29, 2025.
- Total shares outstanding as of April 30, 2025: 6,583,382.
- Shares represented at meeting (proxy or in person): 5,288,388 (approx. 80.3% of outstanding).
- Richard Vincent and Shiv Kapoor were elected to Class II Director positions.
- David Gryska received a significant number of withheld votes (1,313,237) compared to the other nominees.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
Forte Biosciences, Inc. filed an 8-K to furnish its quarterly financial results for the period ending March 31, 2025. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Reporting date: May 15, 2025
- Financial period covered: Quarter ended March 31, 2025
- The filing includes Exhibit 99.1 containing the press release of financial results.
- Signed by Antony Riley, Chief Financial Officer.
Forte Biosciences, Inc. announced the date for its upcoming Annual Meeting of Stockholders, scheduled for May 29, 2025. The filing provides updated deadlines for stockholder proposals and director nominations in accordance with SEC rules.
📋 Key Facts
- Annual Meeting of Stockholders is scheduled for May 29, 2025.
- The meeting date is more than 30 days before the anniversary of the 2024 annual meeting, necessitating revised proposal deadlines.
- Deadline for stockholder proposals to be included in proxy materials (Rule 14a-8) is April 28, 2025.
- Deadline for director nominations or other non-proxy material proposals is also April 28, 2025.
- Compliance with universal proxy rules requires notice of solicitation for non-company nominees by April 28, 2025.
Forte Biosciences, Inc. filed an 8-K to furnish its press release regarding financial results for the fourth quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024.
- Report date: March 31, 2025; Filing date: April 4, 2025.
- The filing includes Exhibit 99.1 containing the press release of financial results.
Forte Biosciences, Inc. announced that stockholders approved the Amendment and Restatement of the 2021 Equity Incentive Plan during a Special Meeting held on January 24, 2025.
📋 Key Facts
- Stockholders approved the A&R 2021 Equity Incentive Plan at a Special Meeting on Jan 24, 2025.
- The plan reserves 3,340,000 shares of common stock for issuance, plus any unexercised/forfeited shares from previous plans (max addition of 44,093 shares).
- Total outstanding shares as of Dec 30, 2024: 6,393,323.
- Shares represented at the meeting: 4,032,759 (approx. 63% of outstanding shares).
- The proposal passed with 2,186,796 votes in favor and 470,795 against.
Forte Biosciences, Inc. held an R&D Day on December 3, 2024, to provide clinical development updates for its lead candidate, FB102, across various autoimmune indications. The filing serves as a formal announcement and incorporates presentation materials used during the event.
📋 Key Facts
- Event Date: December 3, 2024 (R&D Day).
- Primary Focus: Updates on the development of FB102 for autoimmune indications.
- Exhibits provided: R&D Day Presentation (99.1) and updated Corporate Presentation (99.2).
Forte Biosciences entered into a $53 million private placement of common stock and pre-funded warrants to institutional investors and management. The deal includes significant board seat rights for major investors OrbiMed and Tybourne.
🚩 Red Flags
- Significant dilution: The issuance of nearly 5 million shares and 4.6 million warrant shares represents a substantial increase in share count.
- Pre-funded warrants with $0.001 exercise price are highly dilutive upon conversion.
- Related-party transaction: Executive officers and senior management participated in the offering, purchasing ~$475,000 of securities.
📋 Key Facts
- Gross proceeds expected to be approximately $53.0 million before expenses.
- Sale of 4,931,389 shares of common stock at $5.552 per share.
- Issuance of pre-funded warrants to purchase 4,615,555 shares at $5.551 per warrant.
- Warrants are immediately exercisable with an exercise price of $0.001 per share.
- OrbiMed and Tybourne have rights to designate one board member each if specific stock performance parameters are met over a 3-year period.
- Company will file a registration statement for the securities within 30 days of closing.
Forte Biosciences, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2024. The filing serves as a formal announcement of the company's recent operational and financial performance via a press release.
📋 Key Facts
- Reporting date: November 14, 2024
- Financial results reported for the quarter ended September 30, 2024
- The filing includes Exhibit 99.1 containing the official press release
- Information under Item 2.02 is furnished, not filed, per SEC regulations
Forte Biosciences announced a significant board restructuring and the dismissal of a legal action brought by Camac Fund, LP. The settlement involved the resignation of two directors, the appointment of two new independent directors, and a $1.5 million payment to plaintiff's counsel.
🚩 Red Flags
- Board turnover: Resignation of two incumbent directors following litigation settlement.
- Legal expense: $1.5 million cash outflow for legal fee settlement.
- Governance shifts: Reclassification of existing directors and creation of a new 'Strategic Committee' to consider capital options.
📋 Key Facts
- Richard Vincent appointed as Director and Audit Committee Chair; Shiv Kapoor appointed as Director and Nominating Committee member.
- Donald A. Williams and Lawrence Eichenfield resigned from the Board effective September 17, 2024.
- The Delaware Court of Chancery entered a dismissal order for Camac Fund, LP v. Wagner, et al., declaring the action moot on September 20, 2024.
- Company agreed to pay $1,500,000.00 to Plaintiff's counsel to resolve claims for attorneys' fees.
- The Standstill Agreement with the Camac Group remains in effect.
- Two existing directors (Steven Kornfeld and Scott Brun) were reclassified from Class II to Class III to maintain board class balance.
Forte Biosciences, Inc. has implemented a 1-for-25 reverse stock split to increase its share price. The transaction became effective as of August 28, 2024.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing compliance regarding minimum bid price requirements).
📋 Key Facts
- Reverse stock split ratio is 1-for-25.
- Effective date: August 28, 2024, at 8:00 a.m. ET.
- The company's common stock began trading on a reverse-split-adjusted basis on Nasdaq under the same ticker symbol 'FBRX'.
- New CUSIP number assigned: 34962G 208.
- Fractional shares will be paid out in cash based on the closing price from August 27, 2024.
- Proportionate adjustments were made to several equity incentive plans and stock purchase plans.
Forte Biosciences, Inc. announced that stockholders approved a reverse stock split at the company's annual meeting held on August 20, 2024. The Board has set a final ratio of 1-for-25, effective August 28, 2024.
🚩 Red Flags
- Reverse stock split (typically used to maintain Nasdaq listing compliance or improve share price perception).
- High number of broker non-votes/withheld votes in director elections suggests potential shareholder dissatisfaction or lack of engagement.
- Significant dilution risk often associated with reverse splits and subsequent equity incentive plan expansions.
📋 Key Facts
- Stockholders approved an amendment to effect a reverse stock split in a range between 1:5 and 1:30.
- The Board has finalized the ratio at 1-for-25.
- The effective date for the reverse split is August 28, 2024.
- Trading on a split-adjusted basis will commence on Nasdaq under ticker 'FBRX' with a new CUSIP (34962G 208).
- No fractional shares will be issued; instead, cash in lieu of fractional shares will be paid based on fair market value.
- The A&R 2021 Equity Incentive Plan was also approved by stockholders.
Forte Biosciences, Inc. filed an 8-K to report its quarterly financial results for the period ended June 30, 2024 and provided an updated corporate presentation.
📋 Key Facts
- Reported financial results for the quarter ended June 30, 2024 via press release (Exhibit 99.1).
- Released an updated corporate presentation used for investor relations (Exhibit 99.2).
- Filed on August 14, 2024.
Forte Biosciences entered into a Standstill and Voting Agreement with the Camac Group to settle a derivative/class action lawsuit. The settlement includes board expansion, appointment of two Camac-selected directors, and the formation of a committee to explore strategic alternatives.
🚩 Red Flags
- Settlement of a lawsuit alleging interference with shareholder voting rights regarding a $25M private placement.
- Formation of a committee to explore 'strategic alternatives' (often code for potential sale, merger, or restructuring).
- Significant restrictions on the Camac Group's ability to engage in activism/proxy contests via a long-term standstill agreement.
📋 Key Facts
- Entered into a Standstill and Voting Agreement with Camac Group (3.5% beneficial ownership) on June 11, 2024.
- The agreement includes a 'Restricted Period' lasting until 15 days prior to the 2028 annual meeting deadline.
- Camac Group must vote in favor of all Board-nominated directors and against any removal of current directors during the restricted period.
- Settlement of Camac Fund, LP v. Paul A. Wagner, et al. regarding a $25M private placement from July 2023.
- Board will expand to nine seats; one incumbent director will resign.
- Two directors selected by Camac (from a list of five candidates) will be appointed to the Board.
- A committee will be formed to explore 'strategic alternatives' for the Company.
- The Company will not renew its Preferred Stock Rights Agreement expiring in July 2024.
Forte Biosciences, Inc. filed an 8-K to report its quarterly financial results for the period ending March 31, 2024 and provided an updated corporate presentation.
📋 Key Facts
- Reported financial results for the quarter ended March 31, 2024 via press release (Exhibit 99.1).
- Updated its corporate presentation used for investor and analyst meetings (Exhibit 99.2).
- Filed on May 13, 2024.
Forte Biosciences, Inc. filed an 8-K to report its financial results for the fourth quarter and fiscal year ended December 31, 2023. The company also provided an updated corporate presentation for investor relations purposes.
📋 Key Facts
- Reporting of Q4 and FY 2023 financial results (as per Item 2.02).
- Release of updated corporate presentation used for investor/analyst meetings (as per Item 8.01).
- Filing date: March 18, 2024.
This is an amendment to a previous 8-K filing regarding the results of a stockholder advisory vote. The Company's Board of Directors has decided to implement a triennial (every three years) frequency for shareholder votes on executive compensation, following a shareholder vote held on September 19, 2023.
📋 Key Facts
- The filing is an Amendment No. 2 to the original 8-K filed on September 20, 2023.
- Stockholders voted on the frequency of advisory votes regarding named executive officer compensation during the Annual Meeting held on September 19, 2023.
- The Board determined that an advisory vote will occur every three years, meaning the next such vote is scheduled no later than 2029.
- Approximately 41.3% of voting stockholders supported a triennial frequency.